Update on antifungal agents for paediatric patients

Groll, Andreas H.; Tragiannidis, Athanasios

doi:10.1111/j.1469-0691.2010.03334.x

Cited by 42 publications

(27 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective chart review, it was found that treatment of osseous coccidioidomycosis with amphotericin B was associated with fewer cases of relapse as compared to azole therapy 14 . Lipid formulations of amphotericin B, including amphotericin B colloidal dispersion, amphotericin B lipid complex and liposomal amphotericin B are associated with less renal toxicity and fewer infusion-related side effects than the conventional amphotericin B deoxycholate 93 .…”

Section: Resultsmentioning

confidence: 99%

Diagnosis and Initial Management of Musculoskeletal Coccidioidomycosis in Children

Shrader²,

Falk³

et al. 2014

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Diagnosis and Initial Management of Musculoskeletal Coccidioidomycosis in Children

Shrader²,

Falk³

et al. 2014

Journal of Pediatric Orthopaedics

View full text Add to dashboard Cite

“…This antifungal has been recently approved by the Food and Drug Administration and the European Medicine Agency for the treatment of invasive aspergillosis, fusariosis and scedosporiosis [3,4]. It is much more potent against Aspergillus than Anfotericina B, and its greater affinity for the 14ademethylase makes it also more potent than fluconazole [2].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis

2011

View full text Add to dashboard Cite

The aim of this article is to report a case of Aspergillus chorioretinitis successfully treated with intravitreal voriconazole based on an interventional case report. An immunodeficient patient, 34 years old, receiving systemic antifungal treatment for 1 month for invasive aspergillosis with necrotizing pneumonia and brain metastasis, who presented with blurred vision in his left eye. Visual acuity (VA) was 20/20 in his right eye, and 8/20 in his left eye. Ophthalmological examination showed a paramacular nodular yellowish chorioretinal lesion with intraretinal hemorrhages, in the absence of vitritis or anterior uveitis. The patient was treated with one dose of intravitreal voriconazole (100 μg/0.1 ml). One week after the intravitreal injection, the patient's VA was 10/20, the retinal lesions had diminished, and the hemorrhages had disappeared. At 3-month follow-up, his AV was 20/20 with a residual retinal scar. The significant and rapid improvement in this patient suggests that early injection of intravitreal voriconazole may be the first therapeutic option in Aspergillus chorioretinitis, obviating the need for vitrectomy.

show abstract

“…All these amphotericin formulations have been used to treat invasive candidiasis in neonates [21–23] despite not having specific guidance for this population on the Food and Drug Administration (FDA) label [24–26]. The European Medicines Agency (EMA) has only approved L-AmB as one of the first-line therapeutic options for the treatment of candidemia and deeply invasive candidiasis [27, 28]. Currently, ABCD manufacturing is suspended [29].…”

Section: Polyenesmentioning

confidence: 99%

Advances in the treatment of invasive neonatal candidiasis

Botero-Calderon

Benjamin

Cohen‐Wolkowiez

2015

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Introduction Invasive candidiasis is responsible for approximately 10% of nosocomial sepsis in very-low-birth-weight (VLBW) infants and is associated with substantial morbidity and mortality. Over the last 2 decades, the antifungal armamentarium against Candida spp. has increased; however, efficacy and safety studies in this population are lacking. Areas covered We reviewed the medical literature and extracted information on clinical and observational studies evaluating the use of antifungal agents in neonates with invasive candidiasis. Expert opinion Efficacy and safety data for antifungals in neonates are lacking, and the majority of studies conducted to date have concentrated on pharmacokinetic/pharmacodynamic evaluations. Unlike other anti-infective agents, efficacy data in the setting of neonatal candidiasis cannot be extrapolated from adult studies due to differences in the pathophysiology of the disease in this population relative to older children and adults. Data collected thus far or data submitted to regulatory agencies for amphotericin B deoxycholate, fluconazole, and micafungin suggest that these are the current agents of choice for this disease in neonates until data for newer antifungal agents become available. For prophylaxis, data from fluconazole randomized controlled trials will be submitted to the regulatory agencies for labeling. Ultimately, the field of therapeutics for neonatal candidiasis will require multidisciplinary collaboration given the numerous challenges associated with conducting clinical trials in neonates.

show abstract

Update on antifungal agents for paediatric patients

Cited by 42 publications

References 84 publications

Diagnosis and Initial Management of Musculoskeletal Coccidioidomycosis in Children

Diagnosis and Initial Management of Musculoskeletal Coccidioidomycosis in Children

Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis

Advances in the treatment of invasive neonatal candidiasis

Contact Info

Product

Resources

About